|
EP4124343A1
(en)
|
2016-10-20 |
2023-02-01 |
I-Mab Biopharma US Limited |
Novel cd47 monoclonal antibodies and uses thereof
|
|
WO2018089508A2
(en)
|
2016-11-08 |
2018-05-17 |
Ablexis, Llc |
Anti-cd47 antibodies
|
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
|
CA3053392A1
(en)
*
|
2017-02-28 |
2018-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antifibrotic activity of cd47 blockade
|
|
EP3661965A4
(en)
|
2017-08-02 |
2022-07-13 |
Phanes Therapeutics, Inc. |
ANTI-CD47 ANTIBODIES AND USES THEREOF
|
|
WO2019095358A1
(zh)
*
|
2017-11-20 |
2019-05-23 |
泰州迈博太科药业有限公司 |
一种靶向cd47与pd-l1的双功能融合蛋白
|
|
US11180552B2
(en)
|
2017-12-01 |
2021-11-23 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
CN112601544A
(zh)
*
|
2018-07-05 |
2021-04-02 |
三钰生物科技股份有限公司 |
人类抗cd47抗体及其用途
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
SG11202104301SA
(en)
*
|
2018-10-31 |
2021-05-28 |
I Mab Biopharma Us Ltd |
Novel cd47 antibodies and methods of using same
|
|
JP7454645B2
(ja)
|
2019-07-16 |
2024-03-22 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖワクチン並びにその作製方法及び使用方法
|
|
EP4045083B1
(en)
|
2019-10-18 |
2024-01-10 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
WO2021113596A2
(en)
*
|
2019-12-05 |
2021-06-10 |
Sorrento Therapeutics, Inc. |
Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
CN113004406B
(zh)
*
|
2019-12-20 |
2022-04-26 |
广东菲鹏制药股份有限公司 |
抗cd47抗体及其应用
|
|
CN117736207A
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
CA3172449A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
WO2022109227A1
(en)
*
|
2020-11-19 |
2022-05-27 |
Icahn School Of Medicine At Mount Sinai |
Combined cancer therapy of b7-h3 and cd47 immune checkpoint inhbitior and methods of use
|
|
KR102757518B1
(ko)
*
|
2020-12-07 |
2025-01-21 |
(주)이노베이션바이오 |
Cd47에 특이적인 항체 및 이의 용도
|
|
WO2022148383A1
(en)
*
|
2021-01-05 |
2022-07-14 |
National Institute Of Biological Sciences, Beijing |
A bispecific antibody targeting gpc3 and cd47
|
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
TW202305006A
(zh)
|
2021-05-07 |
2023-02-01 |
南韓商益免安協公司 |
與ｃｄ４７及ｐｄ—ｌ１特異性結合的雙特異性抗體
|
|
CN117377671A
(zh)
|
2021-06-23 |
2024-01-09 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117480155A
(zh)
|
2021-06-23 |
2024-01-30 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
EP4365197A4
(en)
*
|
2021-06-30 |
2025-05-14 |
Innobation Bio Co., Ltd. |
Humanized antibody specific to CD47 and pharmaceutical composition containing it for the prevention or treatment of CD47-mediated disease
|
|
WO2023076983A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
KR102438419B1
(ko)
*
|
2021-12-01 |
2022-09-01 |
메디포스트(주) |
Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물
|
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
AU2022419982A1
(en)
|
2021-12-22 |
2024-06-06 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
TW202346277A
(zh)
|
2022-03-17 |
2023-12-01 |
美商基利科學股份有限公司 |
Ｉｋａｒｏｓ鋅指家族降解劑及其用途
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
PE20250157A1
(es)
|
2022-04-21 |
2025-01-22 |
Gilead Sciences Inc |
Compuestos de modulacion de kras g12d
|
|
CN119384415A
(zh)
|
2022-07-01 |
2025-01-28 |
吉利德科学公司 |
Cd73化合物
|
|
EP4554628A1
(en)
|
2022-07-12 |
2025-05-21 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
KR20250167002A
(ko)
|
2023-04-11 |
2025-11-28 |
길리애드 사이언시즈, 인코포레이티드 |
Kras 조절 화합물
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025244201A1
(ko)
|
2024-05-22 |
2025-11-27 |
주식회사 이뮨온시아 |
항-cd47 항체를 이용한 진행성 또는 전이성 고형암의 치료 방법
|